Inactive Instrument

All News Lexaria Corp Other OTC

Equities

US52886N2080

End-of-day quote Other OTC Other stock markets
- ^USD	-

07-12	Lexaria Bioscience Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2024	CI
07-10	HC Wainwright Initiates Lexaria Bioscience at Buy Rating With $10 Price Target	MT

All News

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Lexaria Bioscience Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2024	07-12	CI
HC Wainwright Initiates Lexaria Bioscience at Buy Rating With $10 Price Target	07-10	MT
Lexaria Bioscience Corp. Completes Human Pilot Study 2, GLP-1- H2 4-2	07-09	CI
Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study	07-09	AQ
Lexaria Bioscience : Corporate Presentation	07-08	PU
Lexaria Bioscience Corp. Receives New Patents for Antiviral Drug Delivery and for Treating Epilepsy	07-08	CI
Lexaria Bioscience Secures New Antiviral Drug Delivery, Epilepsy Patents	07-08	MT
Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy	07-08	AQ
Lexaria Bioscience Hires Contract Research Organization For 12-week Study	06-18	MT
Lexaria Awards CRO Contract For 12-Week DehydraTECH GLP-1 Chronic Human Study	06-18	AQ
Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study	06-18	CI
Lexaria Bioscience : Corporate Presentation	06-06	PU
Lexaria Bioscience Corp. Announces Dosing Continues in Lexaria's Second GLP-1 Human Pilot Study	06-05	CI
Lexaria Bioscience Completes Dosing in Second Round of Semaglutide Formulations Human Pilot Study	06-05	MT
Dosing Continues in Lexaria's Second GLP-1 Human Pilot Study	06-05	AQ
Lexaria Awards Contract For Third GLP-1 Human Pilot Study	05-23	AQ
Lexaria Bioscience Secures New Hypertension, Epilepsy Patents in US; Shares Rise	05-21	MT
Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy	05-21	AQ
Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study	05-17	AQ
Lexaria Bioscience Corp. Announces Dosing Begins in Comprehensive GLP-1 Animal Study	05-17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Lexaria Corp Other OTC

Equities

US52886N2080

All News

Filters